Drug Classification:

Clopidogrel Bisulfate and Aspirin Tablets belong to the class of medications known as antiplatelet agents. Clopidogrel is a thienopyridine derivative that selectively inhibits the adenosine diphosphate (ADP) receptor on platelets, while aspirin inhibits cyclooxygenase (COX) enzyme, thereby reducing platelet aggregation and preventing blood clot formation.

Formulations:

• Clopidogrel Bisulfate and Aspirin Tablets:
  • Strength: Each tablet contains Clopidogrel 75mg and Aspirin 150mg.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 10 tablets each.

Indications:

Clopidogrel Bisulfate and Aspirin Tablets are indicated for:

• Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction, stroke, or peripheral arterial disease.
• Prevention of atherothrombotic events in patients with acute coronary syndrome (unstable angina, non-ST segment elevation myocardial infarction [NSTEMI], or ST segment elevation myocardial infarction [STEMI]).

Usage:

• Clopidogrel Bisulfate and Aspirin Tablets should be taken orally once daily, preferably with food, unless otherwise directed by a healthcare professional.
• It is important to adhere strictly to the prescribed dosage and administration regimen to maximize therapeutic benefits and minimize the risk of adverse effects.

Dosage:

• The recommended dose of Clopidogrel Bisulfate and Aspirin Tablets is one tablet daily.
• Dosage adjustments may be necessary based on individual patient characteristics and clinical judgment.
• The use of dual antiplatelet therapy with clopidogrel and aspirin should be carefully monitored and tailored to each patient’s specific needs.

Pharmacokinetics:

• Clopidogrel is rapidly absorbed after oral administration and undergoes hepatic metabolism to form its active metabolite, which inhibits platelet aggregation.
• Aspirin is rapidly absorbed in the gastrointestinal tract and irreversibly inhibits COX enzymes, thereby preventing the synthesis of thromboxane A2, a potent platelet aggregator.

Pharmacodynamics:

• Clopidogrel and aspirin exert their antiplatelet effects through different mechanisms, providing complementary inhibition of platelet activation and aggregation.
• By inhibiting platelet function, Clopidogrel Bisulfate and Aspirin Tablets reduce the risk of thrombotic events, including myocardial infarction, stroke, and cardiovascular death.

Side Effects:

• Common side effects associated with Clopidogrel Bisulfate and Aspirin Tablets may include gastrointestinal symptoms such as abdominal pain, dyspepsia, and gastritis.
• Bleeding, including gastrointestinal and intracranial hemorrhage, is a potential adverse effect and may occur with prolonged use of dual antiplatelet therapy.
• Other rare but serious adverse effects such as thrombotic thrombocytopenic purpura (TTP) and neutropenia have been reported and require prompt medical attention.

Experience the comprehensive cardiovascular protection provided by AIT Pharmaceuticals Division’s Clopidogrel Bisulfate and Aspirin Tablets. For more information, please contact us. Your heart health is our priority, and we are committed to delivering safe and effective pharmaceutical solutions.